Tag Archives: After

Pfizer’s Covid efficacy against infection plunges to 20% after six months, data from Qatar shows

Pfizer’s Covid vaccine efficacy against infection plunges to just 20% after six months – but protection against severe illness barely dips, study concludes Pfizer’s protection against catching Covid drops to just 20% within six months Effectiveness against severe illness and death remains high for at least 6 months  The study used data from Qatar, where… Read More »

Just SIX out of every 1 million develop rare heart inflammation after a second dose of vaccine

Just SIX in 1 million people develop rare heart inflammation after a second dose of the Covid vaccine – 85% less than the rate among the unvaccinated, study finds Less than out of every one million people develop myocarditis after the first shot of a Covid vaccine, and around six develop it after the second… Read More »

Bausch pays whopping $300M to settle Glumetza pay-for-delay lawsuit after 800% price hike

Bausch Health, which industry watchers may remember by its former name Valeant, has been riddled in controversy for years over its defense of diabetes med Glumetza. Now, the company will pay millions to put those charges to rest.  Bausch has agreed to dish out $ 300 million to settle a 2019 lawsuit that claimed the Canadian drugmaker… Read More »